388 related articles for article (PubMed ID: 21237288)
21. Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase.
Bergstrom JD; Dufresne C; Bills GF; Nallin-Omstead M; Byrne K
Annu Rev Microbiol; 1995; 49():607-39. PubMed ID: 8561474
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes.
Dudakovic A; Wiemer AJ; Lamb KM; Vonnahme LA; Dietz SE; Hohl RJ
J Pharmacol Exp Ther; 2008 Mar; 324(3):1028-36. PubMed ID: 18083912
[TBL] [Abstract][Full Text] [Related]
23. A role for geranylgeranylation in interleukin-1beta secretion.
Mandey SH; Kuijk LM; Frenkel J; Waterham HR
Arthritis Rheum; 2006 Nov; 54(11):3690-5. PubMed ID: 17075828
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers.
Waller DD; Park J; Tsantrizos YS
Crit Rev Biochem Mol Biol; 2019 Feb; 54(1):41-60. PubMed ID: 30773935
[TBL] [Abstract][Full Text] [Related]
25. The analytical determination of isoprenoid intermediates from the mevalonate pathway.
Nürenberg G; Volmer DA
Anal Bioanal Chem; 2012 Jan; 402(2):671-85. PubMed ID: 21789486
[TBL] [Abstract][Full Text] [Related]
26. Prevention of transplant coronary artery disease by prenylation inhibitors.
Stein W; Schrepfer S; Itoh S; Kimura N; Velotta J; Palmer O; Bartos J; Wang X; Robbins RC; Fischbein MP
J Heart Lung Transplant; 2011 Jul; 30(7):761-9. PubMed ID: 21458297
[TBL] [Abstract][Full Text] [Related]
27. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
Wiemer AJ; Yu JS; Lamb KM; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2008 Jan; 16(1):390-9. PubMed ID: 17905588
[TBL] [Abstract][Full Text] [Related]
28. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
29. Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation and caspase activation.
Agabiti SS; Li J; Wiemer AJ
Cell Death Dis; 2017 Mar; 8(3):e2678. PubMed ID: 28300835
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells.
Tong H; Holstein SA; Hohl RJ
Anal Biochem; 2005 Jan; 336(1):51-9. PubMed ID: 15582558
[TBL] [Abstract][Full Text] [Related]
31. Protein farnesyltransferase: measurement of enzymatic activity in 96-well format using TopCount microplate scintillation counting technology.
Harwood HJ
Anal Biochem; 1995 Apr; 226(2):268-78. PubMed ID: 7793628
[TBL] [Abstract][Full Text] [Related]
32. Selective inhibition of cholesterol biosynthesis in brain cells by squalestatin 1.
Crick DC; Suders J; Kluthe CM; Andres DA; Waechter CJ
J Neurochem; 1995 Sep; 65(3):1365-73. PubMed ID: 7643114
[TBL] [Abstract][Full Text] [Related]
33. Anti-cancer therapy: targeting the mevalonate pathway.
Swanson KM; Hohl RJ
Curr Cancer Drug Targets; 2006 Feb; 6(1):15-37. PubMed ID: 16475974
[TBL] [Abstract][Full Text] [Related]
34. Mevalonate Cascade Inhibition by Simvastatin Induces the Intrinsic Apoptosis Pathway via Depletion of Isoprenoids in Tumor Cells.
Alizadeh J; Zeki AA; Mirzaei N; Tewary S; Rezaei Moghadam A; Glogowska A; Nagakannan P; Eftekharpour E; Wiechec E; Gordon JW; Xu FY; Field JT; Yoneda KY; Kenyon NJ; Hashemi M; Hatch GM; Hombach-Klonisch S; Klonisch T; Ghavami S
Sci Rep; 2017 Mar; 7():44841. PubMed ID: 28344327
[TBL] [Abstract][Full Text] [Related]
35. Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase.
Dufresne C; Wilson KE; Singh SB; Zink DL; Bergstrom JD; Rew D; Polishook JD; Meinz M; Huang L; Silverman KC
J Nat Prod; 1993 Nov; 56(11):1923-9. PubMed ID: 8289063
[TBL] [Abstract][Full Text] [Related]
36. The balance between induction and inhibition of mevalonate pathway regulates cancer suppression by statins: A review of molecular mechanisms.
Ahmadi Y; Ghorbanihaghjo A; Argani H
Chem Biol Interact; 2017 Aug; 273():273-285. PubMed ID: 28668359
[TBL] [Abstract][Full Text] [Related]
37. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
[TBL] [Abstract][Full Text] [Related]
38. Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver.
Keller RK; Zhao Z; Chambers C; Ness GC
Arch Biochem Biophys; 1996 Apr; 328(2):324-30. PubMed ID: 8645011
[TBL] [Abstract][Full Text] [Related]
39. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
Graaf MR; Richel DJ; van Noorden CJ; Guchelaar HJ
Cancer Treat Rev; 2004 Nov; 30(7):609-41. PubMed ID: 15531395
[TBL] [Abstract][Full Text] [Related]
40. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.
Wiemer AJ; Tong H; Swanson KM; Hohl RJ
Biochem Biophys Res Commun; 2007 Feb; 353(4):921-5. PubMed ID: 17208200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
